Table 3.
Correlation between the aberrant expression levels of midkine and conventional tumor markers in patients with breast cancer (n = 147)
|
(a) Midkine and CA15‐3 | ||
|---|---|---|
| CA15‐3 elevation (–) | CA15‐3 elevation (+) | |
| Midkine elevation (–) | 89 (60.1%) | 5 (3.4%) |
| Midkine elevation (+) | 40 (27.2%) | 13 (8.8%) |
|
(b) Midkine and CEA | ||
|---|---|---|
| CEA elevation (–) | CEA elevation (+) | |
| Midkine elevation (–) | 83 (56.5%) | 11 (7.5%) |
| Midkine elevation (+) | 27 (18.4%) | 26 (17.7%) |
|
(c) Midkine and NCCST‐439 | ||
|---|---|---|
| NCCST‐439 elevation (–) | NCCST‐439 elevation (+) | |
| Midkine elevation (–) | 90 (61.2%) | 4 (2.7%) |
| Midkine elevation (+) | 42 (28.6%) | 11 (7.5%) |
P = 0.0006 (χ2‐test).
P < 0.0001 (χ2‐test).
P = 0.0031 (Fisher's exact test).